Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.96 | 0.11 | -0.38 | 0.04 |
| FCF Yield | 7.03% | 5.58% | 6.41% | 6.74% |
| EV / EBITDA | 10.44 | 12.20 | 14.14 | 6.61 |
| Quality | ||||
| ROIC | 15.55% | 11.49% | 7.06% | 8.69% |
| Gross Margin | 75.20% | 73.27% | 73.35% | 73.31% |
| Cash Conversion Ratio | 1.48 | 1.69 | 2.35 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.97% | 2.00% | -4.50% | -3.33% |
| Free Cash Flow Growth | 17.94% | -2.43% | -4.14% | 13.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 0.71 | 1.39 | 0.60 |
| Interest Coverage | 14.03 | 11.15 | 9.52 | 11.11 |
| Efficiency | ||||
| Inventory Turnover | 2.24 | 2.11 | 1.61 | 1.76 |
| Cash Conversion Cycle | 90.70 | 102.23 | 147.04 | 114.48 |